Physician profile
Bryan Vyverberg
NPI 1740272723
$5,785.45
in general payments reported to CMS, 2019-2025
20 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $487 · 2021: $838 · 2022: $1,088 · 2023: $1,694 · 2024: $606 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,584.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,692.95 | 2019-2025 | Spravato |
| Abbvie INC. | $918.01 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $581.40 | 2020-2024 | Caplyta |
| Allergan, INC. | $473.48 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $416.77 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Lundbeck LLC | $404.18 | 2019-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Tris Pharma INC | $233.93 | 2019 | |
| Vanda Pharmaceuticals INC. | $194.34 | 2019-2023 | Hetlioz |
| Supernus Pharmaceuticals, INC. | $151.19 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $148.49 | 2019-2021 | |
| Alkermes, INC. | $136.96 | 2022-2023 | Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $116.82 | 2019-2022 | |
| Corium, LLC | $85.47 | 2021-2023 | Azstarys |
| Ironshore Pharmaceuticals INC. | $54.88 | 2019-2020 | |
| Shire North American Group INC | $44.14 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $39.17 | 2019 | |
| Axsome Therapeutics, INC. | $37.43 | 2022-2024 | Auvelity |
| Jazz Pharmaceuticals INC. | $20.68 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $20.04 | 2022 | |
| Avanir Pharmaceuticals, INC. | $15.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Vyverberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.